Comparison · NCT01512446-a9edc13e
Alendronate vs Placebo: Combination of New Osteoporotic Fractures and Deaths
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Alendronate vs Placebo: Combination of New Osteoporotic Fractures and Deaths. Trial comparisons, record NCT01512446-a9edc13e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01512446-a9edc13e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0233 | 0.00997 | 0.0533 | wilson | |
| Risk in group 2 | 0.0317 | 0.0154 | 0.0639 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00842 | -0.0433 | 0.0257 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.734 | 0.237 | 2.28 | log | |
| Odds ratio, group 1 over group 2 | 0.728 | 0.227 | 2.33 | log | |
| Number needed to treat, for one fewer participant with the outcome on Alendronate than on Placebo | 119 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Alendronate | Alendronate 70 mg, administered orally once weekly | 5 | 215 | OG001 |
| Group 2 | Placebo | Placebo, administered orally once weekly | 7 | 221 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Combination of New Osteoporotic Fractures and Deaths
- Description
- Number of participants with a new osteoporotic fracture or death
- Time frame
- From baseline to study termination (mean duration 5.6 months)
- Population
- Full Analysis Set (all randomized participants)
Source ClinicalTrials.gov
Trial
- Title
- Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
- NCT number
- NCT01512446
- Phases
- PHASE3
- Conditions
- Osteoporosis
- Interventions
- Alendronate, Placebo
- Lead sponsor
- Evangelisches Krankenhaus Lutherhaus gGmbH
- Results first posted
- 2019-01-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01512446?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01512446-a9edc13e